NCT04637633

Topical Cyclosporine-A for Management of Epiphora

Topical Cyclosporine-A for Management of Epiphora in Eyes With Acquired Punctal Stenosis

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Farwaniya Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

to investigate the clinical outcomes and tolerances of Cyclosporine A (CsA) in treating epiphora in eyes with acquired punctum stenosis

Detailed description

a prospective study included patients who were referred to our outpatient clinics in Farwanyia hospital, Kuwait during the period between July 2019 and January 2020, having symptomatic epiphora associated with severe acquired lower punctal stenosis. Patients were treated with topical 0.05% CsA on twice daily dose with topical preservative free artificial tears Q.I. D. Patients were followed up monthly for at least 3 months by epiphora grading, Fluorescein dye disappearance test (FDT) and evaluating the patient satisfaction

Conditions

• Epiphora

Interventions

Type	Name	Description
DRUG	topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,	topical preservative free artificial tears Q.I. D.

Timeline

• Start date: 2020-08-15
• Primary completion: 2020-10-30
• Completion: 2020-11-01
• First posted: 2020-11-20
• Last updated: 2020-11-23

Locations

1 site across 1 country: Kuwait